U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Neuroblastoma

MedGen UID:
78867
•Concept ID:
C0278695
•
Neoplastic Process
Synonym: Relapsed Neuroblastoma

Definition

The reemergence of neuroblastoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Neuroblastoma

Professional guidelines

PubMed

Multimodality treatment for recurrent neuroblastoma in the central nervous system.
Desai AV, Elmuti L, Cahaney C, De Guzman RM, Streby KA, Cohn SL
Pediatr Blood Cancer 2023 Apr;70(4):e30227. Epub 2023 Jan 31 doi: 10.1002/pbc.30227. PMID: 36720647
Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.
Saulnier Sholler GL, Bond JP, Bergendahl G, Dutta A, Dragon J, Neville K, Ferguson W, Roberts W, Eslin D, Kraveka J, Kaplan J, Mitchell D, Parikh N, Merchant M, Ashikaga T, Hanna G, Lescault PJ, Siniard A, Corneveaux J, Huentelman M, Trent J
Cancer Med 2015 Jun;4(6):871-86. Epub 2015 Feb 26 doi: 10.1002/cam4.436. PMID: 25720842Free PMC Article
Detection and treatment of minimal residual disease in high-risk neuroblastoma.
Reynolds CP
Pediatr Transplant 2004 Jun;8 Suppl 5:56-66. doi: 10.1111/j.1398-2265.2004.00216.x. PMID: 15125707

Recent clinical studies

Etiology

Allele-specific expression reveals genes with recurrent cis-regulatory alterations in high-risk neuroblastoma.
Sen A, Huo Y, Elster J, Zage PE, McVicker G
Genome Biol 2022 Mar 4;23(1):71. doi: 10.1186/s13059-022-02640-y. PMID: 35246212Free PMC Article
Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
Fransson S, Martinez-Monleon A, Johansson M, Sjöberg RM, Björklund C, Ljungman G, Ek T, Kogner P, Martinsson T
Sci Rep 2020 Dec 31;10(1):22432. doi: 10.1038/s41598-020-78370-7. PMID: 33384420Free PMC Article
Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma.
Bagley AF, Grosshans DR, Philip NV, Foster J, McAleer MF, McGovern SL, Lassen-Ramshad Y, Mahajan A, Paulino AC
Pediatr Blood Cancer 2019 Aug;66(8):e27786. Epub 2019 May 2 doi: 10.1002/pbc.27786. PMID: 31050179Free PMC Article
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR
Cancer 2017 Dec 15;123(24):4914-4923. Epub 2017 Sep 8 doi: 10.1002/cncr.30934. PMID: 28885700Free PMC Article
Children's Oncology Group's 2013 blueprint for research: neuroblastoma.
Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, Hogarty M; COG Neuroblastoma Committee
Pediatr Blood Cancer 2013 Jun;60(6):985-93. Epub 2012 Dec 19 doi: 10.1002/pbc.24433. PMID: 23255319

Diagnosis

Allele-specific expression reveals genes with recurrent cis-regulatory alterations in high-risk neuroblastoma.
Sen A, Huo Y, Elster J, Zage PE, McVicker G
Genome Biol 2022 Mar 4;23(1):71. doi: 10.1186/s13059-022-02640-y. PMID: 35246212Free PMC Article
Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
Fransson S, Martinez-Monleon A, Johansson M, Sjöberg RM, Björklund C, Ljungman G, Ek T, Kogner P, Martinsson T
Sci Rep 2020 Dec 31;10(1):22432. doi: 10.1038/s41598-020-78370-7. PMID: 33384420Free PMC Article
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR
Cancer 2017 Dec 15;123(24):4914-4923. Epub 2017 Sep 8 doi: 10.1002/cncr.30934. PMID: 28885700Free PMC Article
Pediatric cancer genomics, a play rather than a portrait.
Ramaswamy V, Taylor MD
Nat Genet 2015 Aug;47(8):851-2. doi: 10.1038/ng.3366. PMID: 26220132
New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.
Cole KA, Maris JM
Clin Cancer Res 2012 May 1;18(9):2423-8. Epub 2012 Mar 16 doi: 10.1158/1078-0432.CCR-11-1409. PMID: 22427348Free PMC Article

Therapy

Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk D, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields AF, Cheung NV, Lum LG
J Immunother Cancer 2024 Mar 21;12(3) doi: 10.1136/jitc-2023-008744. PMID: 38519053Free PMC Article
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
Cole KA, Ijaz H, Surrey LF, Santi M, Liu X, Minard CG, Maris JM, Voss S, Reid JM, Fox E, Weigel BJ
Cancer 2023 Jul 15;129(14):2245-2255. Epub 2023 Apr 20 doi: 10.1002/cncr.34786. PMID: 37081608Free PMC Article
hu3F8 for resistant or recurrent neuroblastoma.
Burki TK
Lancet Oncol 2018 Nov;19(11):e583. Epub 2018 Sep 27 doi: 10.1016/S1470-2045(18)30738-1. PMID: 30269905
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR
Cancer 2017 Dec 15;123(24):4914-4923. Epub 2017 Sep 8 doi: 10.1002/cncr.30934. PMID: 28885700Free PMC Article
Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cooper JP, Reynolds CP, Cho H, Kang MH
Exp Biol Med (Maywood) 2017 Jun;242(11):1178-1184. Epub 2017 Apr 21 doi: 10.1177/1535370217706952. PMID: 28429653Free PMC Article

Prognosis

Allele-specific expression reveals genes with recurrent cis-regulatory alterations in high-risk neuroblastoma.
Sen A, Huo Y, Elster J, Zage PE, McVicker G
Genome Biol 2022 Mar 4;23(1):71. doi: 10.1186/s13059-022-02640-y. PMID: 35246212Free PMC Article
Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
Fransson S, Martinez-Monleon A, Johansson M, Sjöberg RM, Björklund C, Ljungman G, Ek T, Kogner P, Martinsson T
Sci Rep 2020 Dec 31;10(1):22432. doi: 10.1038/s41598-020-78370-7. PMID: 33384420Free PMC Article
Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma.
Bagley AF, Grosshans DR, Philip NV, Foster J, McAleer MF, McGovern SL, Lassen-Ramshad Y, Mahajan A, Paulino AC
Pediatr Blood Cancer 2019 Aug;66(8):e27786. Epub 2019 May 2 doi: 10.1002/pbc.27786. PMID: 31050179Free PMC Article
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR
Cancer 2017 Dec 15;123(24):4914-4923. Epub 2017 Sep 8 doi: 10.1002/cncr.30934. PMID: 28885700Free PMC Article
New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.
Cole KA, Maris JM
Clin Cancer Res 2012 May 1;18(9):2423-8. Epub 2012 Mar 16 doi: 10.1158/1078-0432.CCR-11-1409. PMID: 22427348Free PMC Article

Clinical prediction guides

Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk D, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields AF, Cheung NV, Lum LG
J Immunother Cancer 2024 Mar 21;12(3) doi: 10.1136/jitc-2023-008744. PMID: 38519053Free PMC Article
Allele-specific expression reveals genes with recurrent cis-regulatory alterations in high-risk neuroblastoma.
Sen A, Huo Y, Elster J, Zage PE, McVicker G
Genome Biol 2022 Mar 4;23(1):71. doi: 10.1186/s13059-022-02640-y. PMID: 35246212Free PMC Article
Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma.
Bagley AF, Grosshans DR, Philip NV, Foster J, McAleer MF, McGovern SL, Lassen-Ramshad Y, Mahajan A, Paulino AC
Pediatr Blood Cancer 2019 Aug;66(8):e27786. Epub 2019 May 2 doi: 10.1002/pbc.27786. PMID: 31050179Free PMC Article
Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cooper JP, Reynolds CP, Cho H, Kang MH
Exp Biol Med (Maywood) 2017 Jun;242(11):1178-1184. Epub 2017 Apr 21 doi: 10.1177/1535370217706952. PMID: 28429653Free PMC Article
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.
London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, Matthay KK
J Clin Oncol 2011 Aug 20;29(24):3286-92. Epub 2011 Jul 18 doi: 10.1200/JCO.2010.34.3392. PMID: 21768459Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...